In this section...
ESE Funding Sources
President-elect position – Candidate 1 of 2
Name of Nominee:
Professor of Endocrinology, University Vita-Salute San Raffaele Milano, Italy
Speciality in endocrinology/main field of expertise:
Basic, clinical or both:
FURTHER INFORMATION (pdf)
Andrea Giustina is Professor of Endocrinology and Metabolism and Director of the Chair of Endocrinology at the University Vita-Salute San Raffaele of Milano, Italy. He is President of GIOSEG (Glucocorticoid Induced Osteoporosis and Skeletal Endocrinology Group). Professor Giustina has published more than 380 original papers (330 in peer-reviewed international journals) in the area of growth hormone neuroregulation, acromegaly and growth hormone deficiency, skeletal endocrinology, with particular reference to secondary and drug-induced osteoporosis, diabetes and clinical neuroendocrinology. He was previously a member of the editorial board of JCE&M and Clinical Endocrinology, and is currently Editor-in-Chief of Endocrine and one of the Editors of Pituitary. Professor Giustina is President of the Pituitary Society. He was member of the Executive Committee of the European Society of Endocrinology, the International Society of Endocrinology, and the Board of Directors of the Pituitary Society. He was previously a member of the Journal Managing Subcommittee of the Endocrine Society, Chairman of the Clinical Initiatives Committee of the Pituitary Society and of the Nomination Committee of the European Society of Endocrinology. He currently chairs the Committee for International Affairs of the Italian Society of Endocrinology.
ESE is a young Society that within its 10 years of existence already met significant milestones, as the organization of the Annual European Congresses which have become a must for many European endocrinologists, the Postgraduate Basic and Clinical courses and thematic events. Relevant ongoing clinical initiatives as the European core curriculum in Endocrinology and the publication of ESE guidelines have been highly successful. These activities have been meritoriously initiated and implemented by our Past Presidents who have succesfully led us in important development initiatives. The incoming President will have to deal with the following challenges and opportunities in the next years:
1. To increase the membership to better position European endocrinology as a key global player. In total, Europe harbours 18,000 active endocrinologists and ESE should be the home to best unite and professionally integrate all of them. Along this line we need to attract to the Society all those young clinicians and basic researchers around Europe who are interested in endocrine diseases and to involve them into the activities of our Society, together with the young faculty who are already members.
2. We all know that the European Union is facing critical challenges, which have recently been compounded by Brexit. Differences in languages and cultures, regional economic imbalance and the massive burden of immigration have recently more divided than united the European citizens. With the establishment of ECAS with its detailed knowledge of national and regional matters ESE has made an important effort to reach out and really engage with our members everywhere on our Continent. However, there still remains much to do to in this area. Based on my personal experience as ESE executive board member and past-President of ESE’s Nomination Committee, energetic efforts should be made to enable equal representation in all the Society roles for western and eastern countries. We should aim to transcend language and economic barriers to allow harmonious and productive professional growth of endocrinology in all Europe.
3. In Europe, many successful Endocrine subspecialty Societies already exist. An important task of ESE will be to strengthen the links with these Societies and to involve them in the Program of the Annual Congress or in the joint organization of the thematic events. Along these lines, we should also embrace the inclusion of colleagues who work side by side with us such as Endocrine Surgeons and Endocrine Pathologists. From both a clinical efficiency perspective, as well as most importantly in the best interests of our endocrine patients, these improved relationships may facilitate the creation of integrated Endocrine-Surgical Units within which all related specialists may work harmoniously and effectively together to assure the best patient outcomes. This initiative may also be responsive to the needs of public health agencies and payors who are appropriately insisting on value-based therapeutic outcomes for all diseases.
4. Besides the meritorious initiative of Endo ERN, which is devoted to the care of rare endocrine diseases in Europe, a common experience is that many major endocrine diseases are not anymore recognized as such and are therefore more frequently both clinically and culturally dealt with by other specialists. Classic examples of this trend being osteoporosis, obesity, diabetes and reproductive endocrinology. A major task of ESE will be to bring back the endocrinologist as a key player in the management of these important disorders. Moreover, emerging areas such as environmental endocrinology including endocrine disruptors need to be pursued to better deal with the rapidly emerging requests from European citizens and Health Authorities;
5. Basic and translational endocrine science are the major strengths of our discipline. ESE should play an increasingly active role in fostering training of basic endocrinologists in Europe by funding experiences in established labs. Moreover, ESE should work to improve access of endocrine investigators to European research funds and also establish a Task Force to lead development of a framework for integrating basic and clinical researchers to successfully compete for specific funded European research.
© European Society of Endocrinology | Disclaimer | Privacy